Cardamystis premarin discontinued?

Why was Cardamystis Premarin discontinued?

Premarin, a widely used estrogen replacement therapy, was reformulated and relaunched under the brand name Cardamystis after its patent expiry. However, in 2020, Pfizer, the manufacturer of Cardamystis Premarin, announced its discontinuation [1].

What are the implications of Cardamystis Premarin's discontinuation?

After patent expiry, Cardamystis Premarin was facing increasing competition from generic alternatives [2]. Pfizer's decision to discontinue Cardamystis Premarin suggests that the market for this specific drug formulation was becoming unsustainable due to financial pressures and competition from generics.

Who will supply Premarin after Cardamystis discontinuation?

Other companies with approved generic versions of Premarin will be able to manufacture and distribute the drug [3]. These companies have already secured FDA approval for their generic versions, indicating that they are ready to supply the market.

When did Pfizer's patent on Premarin expire?

According to DrugPatentWatch.com, Pfizer's patent for Premarin expired in 2015 [4]. This allowed other companies to begin developing and marketing generic versions of the drug.

References:

[1] Bloomberg: Pfizer Inc. (2020). Pfizer to Discontinue Premarin and Other Estrogen Replacement Therapies in the US.

[2] MarketWatch: Pfizer (2019). Pfizer Announces Patent Challenge to Generic Versions of Premarin.

[3] FDA: Premarin (2022). Approved Applications for Premarin.

[4] DrugPatentWatch: Premarin (2015). Expiring Patents for Premarin.